Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients

Neurogastroenterology and Motility

Volumn 26, Issue 5, 2014, Pages 705-714

  Ludidi, S ^a   Jonkers, D M ^a   Koning, C J ^b   Kruimel, J W ^a   Mulder, L ^b   van der Vaart, I B ^b   Conchillo, J M ^a   Masclee, A A M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b WINCLOVE PROBIOTICS   (Netherlands)

Author keywords

Barostat; Irritable bowel syndrome; Probiotics; Symptoms; Visceral hypersensitivity

Indexed keywords

PROBIOTIC AGENT;

ADULT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERALGESIA; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VISCERAL PAIN;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERALGESIA; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PROBIOTICS; TREATMENT OUTCOME; VISCERAL PAIN;

EID: 84898814240     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12320     Document Type: Article

References (50)

1. Talley NJ. Irritable bowel syndrome: definition, diagnosis and epidemiology. Baillieres Best Pract Res Clin Gastroenterol 1999; 13: 371-84.
2. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40, 000 subjects. Aliment Pharmacol Ther 2003; 17: 643-50.
3. Piche T, Barbara G, Aubert P, Bruley des Varannes S, Dainese R, Nano JL, Cemon C, Stanghellini V et al. Impaired intestinal barrier integrity in thecolon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009; 58: 196-201.
4. Camilleri M, Lasch K, Zhou W. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastointest Liver Physiol 2012; 303: G775-85.
5. Spiller R, Lam C. An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome. J Neurogastroenterol Motil 2012; 18: 258-68.
6. Isolauri E, Salminen S, Ouwehand AC. Microbial-gut interactions in health and disease. Probiotics. Best Pract Res Clin Gastroenterol 2004; 18: 299-313.
7. Mai V, Braden CR, Heckendorf J, Pironis B, Hirshon JM. Monitoring of stool microbiota in subjects with diarrhea indicates distortions in composition. J Clin Microbiol 2006; 44: 4550-2.
8. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 40-52.
9. Grundmann O, Yoon SL. Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners. J Gastroenterol Hepatol 2010; 25: 691-9.
10. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 2009; 9: 15.
11. Nozu T, Okumura T. Visceral sensation and irritable bowel syndrome; with specialreference to comparison with functional abdominal pain syndrome. J Gastroenterol Hepatol 2011; 26(Suppl. 3): 122-7.
12. Posserud I, Syrous A, Lindstrom L, Tack J, Abrahamsson H, Simren M. Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology 2007; 133: 1113-23.
13. van der Veek PP, Van Rood YR, Masclee AA. Symptom severity but not psychopathology predicts visceral hypersensitivity in irritable bowel syndrome. Clin Gastroenterol Hepatol 2008; 6: 321-8.
14. Zhou Q, Verne GN. New insights into visceral hypersensitivity-clinical implications in IBS. Nat Rev Gastroenterol Hepatol 2011; 8: 349-55.
15. Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 2009; 146: 41-6.
16. Larauche M. Novel insights in the role of peripheral corticotropin-releasing factor and mast cells in stress-induced visceral hypersensitivity. Neurogastroenterol Motil 2012; 24: 201-5.
17. Binshtok AM, Wang H, Zimmermann K, Amaya AF, Vardeh D, Shi L, Brenner GJ, Ji RR et al. Nociceptors are interleukin-1beta sensors. J Neurosci 2008; 28: 14062-73.
18. Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994; 107: 271-93.
19. Ait-Belgnaoui A, Bradesi S, Fioramonti J, Theodorou V, Bueno L. Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: role of myosin light chain kinase. Pain 2005; 113: 141-7.
20. Zhou Q, Souba WW, Croce CM, Verne GN. MicroRNA-29a regulates intestinal membranepermeability in patients with irritable bowel syndrome. Gut 2010; 59: 775-84.
21. Agostini S, Goubern M, Tondereau V, Salvador-Cartier C, Bezirard V, Leveque M, Keranen H, Theodorou V et al. A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats. Neurogastroenterol Motil 2012; 24: 376-e172.
22. Rousseaux C, Thuru X, Gelot A, Barmich N, Neut C, Dubuquoy L, Dubuquoy C, Merour E et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007; 13: 35-7.
23. Simren M, Barbara G, Flint HJ et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2012; 62: 159-76.
24. Whelan K. Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. Curr Opin Clin Nutr Metab Care 2011; 14: 581-7.
25. Clarke G, Cryan JF, Dinan TG, Quigley EM. Review article: probiotics for the treatment of irritable bowel syndrome-focus on lactic acid bacteria. Aliment Pharmacol Ther 2012; 35: 403-13.
26. O'Donnell LJ, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. BMJ 1990; 300: 439-40.
27. Timmerman HM, Niers LE, Ridwan BU, Koning CJ, Mulder L, Akkermans LM, Rombouts FM, Rijkers GT. Design of a multispecies probiotic mixture to prevent infectious complications in critically ill patients. Clin Nutr 2007; 26: 450-9.
28. de Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 2003; 10: 133-9.
29. Malago JJ, Tooten PC, Koninkx JF. Anti-inflammatory properties of probiotic bacteria on Salmonella-induced IL-8 synthesis in enterocyte-like Caco-2 cells. Benef Microbes 2010; 1: 121-30.
30. Ludidi S, Conchillo JM, Keszthelyi D et al. Does meal ingestion enhance sensitivity of visceroperception assessment in irritable bowel syndrome? Neurogastroenterol Motil 2012; 24: 47-53, e43.
31. Ludidi S, Conchillo JM, Keszthelyi D et al. Rectal hypersensitivity as hallmark for irritable bowel syndrome: defining the optimal cutoff. Neurogastroenterol Motil 2012; 24: 729-e346.
32. Lindsey PJ, Kaufmann J. Analysis of a longitudinal ordinal response clinical trial using dynamic models. J R Stat Soc Series B: Stat Methodol, 2004: 53.
33. Vanhoutvin SA, Troost FJ, Kilkens TO, Lindsey PJ, Hamer HM, Jonkers DM, Venema K, Brummer RJ. The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil 2009; 21: 952-e976.
34. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010; 59: 325-32.
35. Hammer HF, Phillips SF, Camilleri M, Hanson RB. Rectal tone, distensibility, and perception: reproducibility and response to different distensions. Am J Physiol 1998; 274: G584-90.
36. Dunlop SP, Jenkins D, Spiller RC. Age-related decline in rectal mucosal lymphocytes and mast cells. Eur J Gastroenterol Hepatol 2004; 16: 1011-5.
37. Patel SM, Statson WB, Legedza A, Ock SM, Kaptchuk TJ, Conboy L, Canenguez K, Park JK et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 2005; 17: 332-40.
38. Pitz M, Cheang M, Bernstein CN. Defining the predictors of the placebo response in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 237-47.
39. Rogers NJ, Mousa SA. The shortcomings of clinical trials assessing the efficacy ofprobiotics in irritable bowel syndrome. J Altern Complement Med 2012; 18: 112-9.
40. Bouhnik Y, Neut C, Raskine L, Michel C, Riottot M, Andrieut C, Guillemot F, Dyard F et al. Prospective, randomized, parallel-group trial to evaluate the effects of lactulose and polyethylene glycol-4000 on colonic flora in chronic idiopathic constipation. Aliment Pharmacol Ther 2004; 19: 889-99.
41. Florent C, Flourie B, Leblond A, Rautureau M, Bernier JJ, Rambaud JC. Influence of chronic lactulose ingestion on the colonic metabolism of lactulose in man (an in vivo study). J Clin Invest 1985; 75: 608-13.
42. Camilleri M, Mayer EA. Developing irritable bowel syndrome guidelines through meta-analyses: does the emperor really have new clothes? Gastroenterology 2009; 137: 766-9.
43. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001; 13: 1143-7.
44. Whorwell PJ, Altringer L, Morel J, Charbonneau D, O'Mahony L, Kiely B, Shanahan F, Quigley EM. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 1581-90.
45. Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, Thomforde G, Zinsmeister AR. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Hepatol 2005; 17: 687-96.
46. Zeng J, Li YQ, Zuo XL, Zhen YB, Yang J, Liu CH. Clinical trial: effect of activelactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2008; 28: 994-1002.
47. Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002; 47: 2615-20.
48. Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P. A double blind randomized controlled trial of a probiotic combination in 100 patients withirritable bowel syndrome. Gastroenterol Clin Biol 2008; 32: 147-52.
49. Timmerman HM, Koning CJ, Mulder L, Rombouts FM, Beynen AC. Monostrain, multistrain and multispecies probiotics-A comparison of functionality and efficacy. Int J Food Microbiol 2004; 96: 219-33.
50. Chapman CM, Gibson GR, Rowland I. Health benefits of probiotics: are mixtures more effective than single strains? Eur J Nutr 2011; 50: 1-17.